GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Cyclically Adjusted PS Ratio

Progenics Pharmaceuticals (FRA:PGP) Cyclically Adjusted PS Ratio : (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Progenics Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Progenics Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Progenics Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2020 is calculated as:

For example, Progenics Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2020 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2020 (Change)*Current CPI (Mar. 2020)
=0.065/108.9015*108.9015
=0.065

Current CPI (Mar. 2020) = 108.9015.

Progenics Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201006 0.058 91.962 0.069
201009 0.046 92.162 0.054
201012 0.049 92.474 0.058
201103 0.051 94.283 0.059
201106 1.528 95.235 1.747
201109 0.125 95.727 0.142
201112 0.051 95.213 0.058
201203 0.050 96.783 0.056
201206 0.043 96.819 0.048
201209 0.026 97.633 0.029
201212 0.180 96.871 0.202
201303 0.034 98.209 0.038
201306 0.027 98.518 0.030
201309 0.011 98.790 0.012
201312 0.036 98.326 0.040
201403 0.021 99.695 0.023
201406 0.016 100.560 0.017
201409 0.444 100.428 0.481
201412 -0.007 99.070 -0.008
201503 0.003 99.621 0.003
201506 0.025 100.684 0.027
201509 0.018 100.392 0.020
201512 0.067 99.792 0.073
201603 0.031 100.470 0.034
201606 0.108 101.688 0.116
201609 0.683 101.861 0.730
201612 0.062 101.863 0.066
201703 0.031 102.862 0.033
201706 0.035 103.349 0.037
201709 0.032 104.136 0.033
201712 0.047 104.011 0.049
201803 0.036 105.290 0.037
201806 0.045 106.317 0.046
201809 0.057 106.507 0.058
201812 0.034 105.998 0.035
201903 0.045 107.251 0.046
201906 0.104 108.070 0.105
201909 0.059 108.329 0.059
201912 0.157 108.420 0.158
202003 0.065 108.902 0.065

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Progenics Pharmaceuticals  (FRA:PGP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Progenics Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (FRA:PGP) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga 06-16-2023